<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377299</url>
  </required_header>
  <id_info>
    <org_study_id>052006-27</org_study_id>
    <nct_id>NCT00377299</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence</brief_title>
  <official_title>A Double-blind, Placebo-controlled Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bipolar disorder (BD) is a common and severe psychiatric illness. Drug and alcohol abuse are
      very common in people with BD and other mood disorders and are associated with increased
      rates of hospitalization, violence towards self and others, medication non-adherence and
      cognitive impairment. However, few studies have investigated the treatment of dual-diagnosis
      patients as substance use is frequently an exclusion criterion in clinical trials of patients
      with BD. To address this need, we have developed a research program that explores the
      pharmacotherapy of people with BD and substance related-disorders. A potentially very
      interesting treatment for BD is citicoline. Some data suggest that this supplement may
      stabilize mood, decrease drug use and craving, and improve memory. We found promising results
      with citicoline in patients with BD and cocaine dependence. In recent years the use of
      amphetamine and methamphetamine has become an important public health concern. However,
      virtually no research has been conducted on the treatment of amphetamine abuse. We propose a
      double-blind placebo controlled prospective trial of citicoline in a group of 60 depressed
      outpatients with bipolar disorder, depressed phase or major depressive disorder and
      amphetamine abuse/dependence, to explore the safety and tolerability of citicoline, and its
      efficacy for mood symptoms, stimulant use and craving and its impact on cognition. Our goal
      is to determine which symptoms (e.g. mood, cognition, substance use) citicoline appears to be
      most effective and estimate effect sizes for future work.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty outpatients meeting the inclusion and exclusion criteria will be enrolled after
      completing an Institutional Review Board (IRB)-approved informed consent process. Baseline
      evaluation will include a medical and psychiatric history, structured clinical interview for
      Diagnostic and Statistical Manual (DSM-IV) (SCID), mood assessment with the Inventory of
      Depressive Symptomatology-Self Report (IDS-C), Young Mania Rating Scale (YMRS), and cognitive
      assessment with the Hopkins Auditory Verbal Learning Test (HVLT) (similar to the Rey Auditory
      Verbal Learning Test (RAVLT) but more alternative equivalent versions are available), Stroop
      and computer assessments including Sternberg Memory Task and the Running Memory Continuous
      Performance Test. Alternate but equivalent versions of all cognitive tests, except the
      Stroop, will be used to minimize practice effects with repeated administration. Days and
      amounts of amphetamine and other substance use will be assessed at each visit with urine drug
      screens, and through self-report using the timeline follow-back method. Amphetamine, and
      other drug, craving will be assessed with a visual analogue scales. Citicoline or placebo
      add-on therapy will be given beginning at one tablet (500mg)/day with an increase to two
      tablets 1000 mg/day at week 2, three tables 1500 mg/day at week 4 and four tablets 2000
      mg/day at week 6.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression Symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Inventory of Depressive Symptomatology-Clinician Rated (IDS-C), (a clinician-administered depression scale) is used to assess the severity of depressive symptoms.Scores can range from 0 to 84. The higher the score, the worse the depressive symptoms(worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amphetamine Craving</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Visual Analog Scale (VAS) assessing Methamphetamine craving with a 1-100 scale.Higher values on the VAS scale indicate a higher Methamphetamine craving(worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amphetamine Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant reported days per 7-day week of methamphetamine use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopkins Auditory Verbal Learning Test (HVLT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Hopkins Auditory Verbal Learning Test (HVLT) is a measure of cognition (memory/recall). Raw scores are derived for Total Recall, Delayed Recall, Retention (% retained), and a Recognition Discrimination Index. Raw scores are calculated into T-scores. T-scores are standardized scores on each dimension for each type. A score of 50 represents the mean. A difference of 10 from the mean indicates a difference of one standard deviation. Thus, a score of 60 is one standard deviation above the mean, while a score of 30 is two standard deviations below the mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Color Word Test</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Stroop Color Word Test measures the individual's ability to separate the word and color naming stimuli thus the ability to sort information from the environment and selectively react to this information. The scoring is a measure of time to complete 100 items and the numbers of items that can be completed. THe scores are converted into T-scores which have a mean of 50 and a standard deviation of 10.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Amphetamine Abuse</condition>
  <condition>Amphetamine Dependence</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Citicoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching active medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citicoline</intervention_name>
    <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.</description>
    <arm_group_label>Citicoline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching active medication in all other physical aspects</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18-70 years

          -  Meeting criteria for a current major depressive episode (bipolar I,II, not otherwise
             specified (NOS)

             , depressed phase) or major depressive disorder on the Structured Clinical Interview
             for the Diagnostic and Statistical Manual for Mental Disorders (SCID) with a duration
             of at least 4 weeks

          -  Meeting criteria for amphetamine abuse or dependence with use within 14 days prior to
             baseline

          -  No psychotropic medication changes within 14 days prior to study entry

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Current citicoline therapy

          -  Active suicidal or homicidal ideation with plan and intent

          -  Dementia, mental retardation or other severe cognitive impairment that might interfere
             with the informed consent process

          -  Currently incarcerated at a prison or jail

          -  Severe or life threatening medical condition (e.g. terminal cancer, congestive heart
             failure)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherwood Brown, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychoneuroendocrine Research Program</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <results_first_submitted>September 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2013</results_first_posted>
  <last_update_submitted>July 5, 2013</last_update_submitted>
  <last_update_submitted_qc>July 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amphetamine Abuse</keyword>
  <keyword>Amphetamine Dependence</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Citicoline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty depressed outpatients with methamphetamine dependence were enrolled and randomized for 12 weeks of acute treatment after completing an IRB-approved written informed consent The study was conducted at the UT Southwestern Medical Center in Dallas. The first participant was enrolled on 10/11/06 and the final assessment was on 4/7/09.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Citicoline</title>
          <description>Citicoline add-on therapy was given beginning at one tablet(500mg/day) with an increase to two tablets(1000mg/day) at week 2, three tablets(1500mg/day)at week 4 and four tablets (2000mg/day) at week 6. Patients remained on 2000mg/day throughout the remaining weeks of the study (week 12). Doses were decreased, if needed, due to side effects.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo identical in appearance to the medication was given beginning at one tablet with an increase to two tablets at week 2, three tablets at week 4 and four tablets at week 6. Patients remained on four tables throughout the remaining weeks of the study (week 12). Doses were decreased, if needed, due to side effects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Citicoline</title>
          <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="9.6"/>
                    <measurement group_id="B2" value="34.0" spread="7.4"/>
                    <measurement group_id="B3" value="37.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Depression Symptoms</title>
        <description>Inventory of Depressive Symptomatology-Clinician Rated (IDS-C), (a clinician-administered depression scale) is used to assess the severity of depressive symptoms.Scores can range from 0 to 84. The higher the score, the worse the depressive symptoms(worse outcome).</description>
        <time_frame>12 weeks</time_frame>
        <population>The intent to treat (ITT) group includes all who returned for at least one post baseline visit. Analysis uses Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Citicoline</title>
            <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Symptoms</title>
          <description>Inventory of Depressive Symptomatology-Clinician Rated (IDS-C), (a clinician-administered depression scale) is used to assess the severity of depressive symptoms.Scores can range from 0 to 84. The higher the score, the worse the depressive symptoms(worse outcome).</description>
          <population>The intent to treat (ITT) group includes all who returned for at least one post baseline visit. Analysis uses Last Observation Carried Forward (LOCF) method.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="2.5"/>
                    <measurement group_id="O2" value="33.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Significance was set at a p value of ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amphetamine Craving</title>
        <description>Visual Analog Scale (VAS) assessing Methamphetamine craving with a 1-100 scale.Higher values on the VAS scale indicate a higher Methamphetamine craving(worse outcome).</description>
        <time_frame>12 Weeks</time_frame>
        <population>ITT includes those returning for at least one post baseline visit. LOCF used for end point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Citicoline</title>
            <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Amphetamine Craving</title>
          <description>Visual Analog Scale (VAS) assessing Methamphetamine craving with a 1-100 scale.Higher values on the VAS scale indicate a higher Methamphetamine craving(worse outcome).</description>
          <population>ITT includes those returning for at least one post baseline visit. LOCF used for end point data.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="8.0"/>
                    <measurement group_id="O2" value="44.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Significance was set at a p value of ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amphetamine Use</title>
        <description>Participant reported days per 7-day week of methamphetamine use.</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT includes those returning for at least one post baseline visit. LOCF used for end point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Citicoline</title>
            <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching Citicoline.</description>
          </group>
        </group_list>
        <measure>
          <title>Amphetamine Use</title>
          <description>Participant reported days per 7-day week of methamphetamine use.</description>
          <population>ITT includes those returning for at least one post baseline visit. LOCF used for end point data.</population>
          <units>days per week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.6"/>
                    <measurement group_id="O2" value="2.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Significance was set at a p value of ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hopkins Auditory Verbal Learning Test (HVLT)</title>
        <description>The Hopkins Auditory Verbal Learning Test (HVLT) is a measure of cognition (memory/recall). Raw scores are derived for Total Recall, Delayed Recall, Retention (% retained), and a Recognition Discrimination Index. Raw scores are calculated into T-scores. T-scores are standardized scores on each dimension for each type. A score of 50 represents the mean. A difference of 10 from the mean indicates a difference of one standard deviation. Thus, a score of 60 is one standard deviation above the mean, while a score of 30 is two standard deviations below the mean.</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT includes those returning for at least one post baseline visit. LOCF used for end point data.</population>
        <group_list>
          <group group_id="O1">
            <title>Citicoline</title>
            <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching Citicoline.</description>
          </group>
        </group_list>
        <measure>
          <title>Hopkins Auditory Verbal Learning Test (HVLT)</title>
          <description>The Hopkins Auditory Verbal Learning Test (HVLT) is a measure of cognition (memory/recall). Raw scores are derived for Total Recall, Delayed Recall, Retention (% retained), and a Recognition Discrimination Index. Raw scores are calculated into T-scores. T-scores are standardized scores on each dimension for each type. A score of 50 represents the mean. A difference of 10 from the mean indicates a difference of one standard deviation. Thus, a score of 60 is one standard deviation above the mean, while a score of 30 is two standard deviations below the mean.</description>
          <population>ITT includes those returning for at least one post baseline visit. LOCF used for end point data.</population>
          <units>T score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="3.8"/>
                    <measurement group_id="O2" value="47.5" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Significance was set at a p value of ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroop Color Word Test</title>
        <description>The Stroop Color Word Test measures the individual's ability to separate the word and color naming stimuli thus the ability to sort information from the environment and selectively react to this information. The scoring is a measure of time to complete 100 items and the numbers of items that can be completed. THe scores are converted into T-scores which have a mean of 50 and a standard deviation of 10.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Citicoline</title>
            <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroop Color Word Test</title>
          <description>The Stroop Color Word Test measures the individual's ability to separate the word and color naming stimuli thus the ability to sort information from the environment and selectively react to this information. The scoring is a measure of time to complete 100 items and the numbers of items that can be completed. THe scores are converted into T-scores which have a mean of 50 and a standard deviation of 10.</description>
          <units>T score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="2.6"/>
                    <measurement group_id="O2" value="54.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Significance was set at a p value of ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Citicoline</title>
          <description>Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injuries Due to Car Accident</sub_title>
                <description>Participant was in a motor vehicle accident.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Drug Overdose</sub_title>
                <description>Overdose.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Car Accident</sub_title>
                <description>Participant was in a motor vehicle accident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Overdose / Suicidal Gesture</sub_title>
                <description>Overdose.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Psychiatric Hospitalization Involuntary</sub_title>
                <description>Psychiatric hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth Abscess and Infection</sub_title>
                <description>Participant reported an abscessed/infected tooth and received amoxycillin.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Panic Attack</sub_title>
                <description>Participant with a history of panic attacks experienced a severe panic attack. Attack resolved without need for medical intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. E. Sherwood Brown, M.D., Ph.D.</name_or_title>
      <organization>UT Southwestern Medical Center at Dallas</organization>
      <phone>214-645-6950</phone>
      <email>sherwood.brown@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

